-
Article
Open AccessEffect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications
Circulating immune cells play a pathogenic role in multiple sclerosis (MS). However, the role of specific lymphocyte subpopulations is not unveiled yet, especially in progressive stages. We aimed to investigat...
-
Article
Open AccessChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis
ChatGPT is an open-source natural language processing software that replies to users’ queries. We conducted a cross-sectional study to assess people living with Multiple Sclerosis’ (PwMS) preferences, satisfac...
-
Article
Open AccessThe ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis
The wearing-off phenomenon is common in people with multiple sclerosis (MS) treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to ocrelizumab in relation to demographic and M...
-
Article
Open AccessIntegration of the expanded disability status scale with ambulation, visual and cognitive tests
The Expanded Disability Status Scale (EDSS) is usually calculated through a neurological examination with self-reported performance. This may lead to incorrect assessment of Functional System scores (FSs). Aim...
-
Article
Open AccessSARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose
COVID-19 vaccines have been recommended to people with multiple sclerosis (pwMS) and, to ensure durable immunity, a third booster dose has been administered in several countries. Data about potential risks ass...
-
Article
Open AccessImpact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study
COVID-19 pandemic has affected the management of multiple sclerosis (MS).
-
Article
Open AccessOcrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes, neutrophils and immunoglobulins: (1) when compared with p...
-
Article
Open AccessPersistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
We aim to provide real-world evidence on the use of ocrelizumab for treating multiple sclerosis (MS), with specific regard to prescription pattern, adherence, persistence, healthcare resource utilization and r...
-
Article
Open AccessMental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience
The current study aimed at exploring the relationship between objective disability, illness perceptions, resilience, fear of COVID-19, and psychological distress (i.e., anxiety, depression, and stress) in peop...
-
Article
Open AccessManagement of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate th...
-
Article
Open AccessCorrection to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
-
Article
Correction to: Disability assessment using Google Maps
-
Article
Disability assessment using Google Maps
To evaluate the concordance between Google Maps® application (GM®) and clinical practice measurements of ambulatory function (e.g., Ambulation Score (AS) and respective Expanded Disability Status Scale (EDSS))...
-
Article
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19
People with multiple sclerosis (MS) may experience sexual dysfunction throughout the disease course. Validated scales to assess sexual dysfunction in MS for Italian patients are lacking. Hence, we aimed at val...
-
Article
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study
Botulinum toxin (BT) is an effective and safe treatment for spasticity, with limited evidence in multiple sclerosis (MS). We aim to describe the use of BT for the management of MS spasticity in the clinical pr...
-
Article
Open AccessPersistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at popula...
-
Article
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis
Aim of this study was to investigate the reliability and validity of 2D linear measures of ventricular enlargement as indirect markers of brain atrophy and possible predictors of clinical disability.
-
Article
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study
Nabiximols is an effective treatment for spasticity in MS. However, treatment discontinuation over-time might occur and predictors of sustained treatment persistence over long-term follow-up in real-world sett...
-
Article
Assessing disability and relapses in multiple sclerosis on tele-neurology
As a consequence of the coronavirus disease 2019 (COVID-19) pandemic, a large amount of consultations will be delivered through tele-medicine, especially for diseases causing chronic disability and requiring i...
-
Article
Open AccessAssociations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis
Differently from the adult multiple sclerosis (MS) population, the predictive value of cognitive impairment in early-onset MS is still unknown. We aim to evaluate whether cognitive performances at disease onse...
